Details.
On-demand online webinar exploring how early cardiometabolic development programmes can generate meaningful pharmacodynamic evidence alongside safety and pharmacokinetics. The discussion covers endpoints beyond weight loss, cardiometabolic comorbidities, earlier involvement of patient populations, and advanced metabolic, biomarker, and functional assessments. Designed for professionals involved in early cardiometabolic drug development, including clinical development, translational medicine, clinical pharmacology, biomarker, clinical science, endpoint strategy, pre-clinical, medical, R&D, and portfolio teams.